Treatment of multiple solitary plasmacytomas with cytokine-induced killer cells

Cytotherapy. 2014 Feb;16(2):278-84. doi: 10.1016/j.jcyt.2013.11.001.

Abstract

Background aims: Currently available treatment methods for advanced plasmacytoma include surgery, chemotherapy, radiotherapy, immunomodulatory agents, hematopoietic stem cell transplantation and donor lymphocyte infusion. We report a case of advanced refractory multiple solitary plasmacytomas in a 68-year-old Asian man with multiple bone lesions, in whom autologous cytokine-induced killer (CIK) cells were administered in an effort to eliminate residual tumor lesions.

Methods: CIK cells were infused monthly for 21 courses.

Results: The patient has survived 63 months since the first hospital visit without disease progression for 40 months.

Conclusions: This case represents the first report of autologous CIK cell immunotherapy used successfully to suppress multiple solitary plasmacytomas and resolve bone lesions.

Keywords: cancer; chemotherapy; cytokine-induced killer cells; immunotherapy; plasmacytoma.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Asian People
  • Bone Neoplasms / immunology
  • Bone Neoplasms / therapy*
  • Cancer Vaccines*
  • Cytokine-Induced Killer Cells / immunology
  • Cytokine-Induced Killer Cells / transplantation*
  • Disease-Free Survival
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunotherapy / methods*
  • Male
  • Plasmacytoma / immunology
  • Plasmacytoma / therapy*
  • Transplantation, Autologous

Substances

  • Cancer Vaccines